The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Common Human UGT1A Polymorphisms and the Altered Metabolism of Irinotecan Active Metabolite 7-Ethyl-10-hydroxycamptothecin (SN-38)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
Tukey, R. H., & Strassburg, C. P. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.581 · Cited by 1,523
Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Belanger, A., Gigleux, S. F., Green, M., Hum, D. W., Iyanagi, T., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199708000-00001 · Cited by 1,183
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
IYER, L., HALL, D., DAS, S., MORTELL, M., RAMIREZ, J., KIM, S., DIRIENZO, A., & RATAIN, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70078-0 · Cited by 356
In Vitro Glucuronidation Using Human Liver Microsomes and The Pore-Forming Peptide Alamethicin
Fisher, M. B., Campanale, K., Ackermann, B. L., VandenBranden, M., & Wrighton, S. A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15100-8 · Cited by 343
Turgeon, D., Carrier, J.-S., Lévesque, E., Hum, D. W., & Bélanger, A. (2001) · Endocrinology · doi:10.1210/endo.142.2.7958 · Cited by 333
Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., & Mackenzie, P. I. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29222-3 · Cited by 301
Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus
Gong, Q.-H., Cho, J. W., Huang, T., Potter, C., Gholami, N., Basu, N. K., Kubota, S., Carvalho, S., Pennington, M. W., Owens, I. S., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00011 · Cited by 272
Akaba, K., Kimura, T., Sasaki, A., Tanabe, S., Ikegami, T., Hashimoto, M., Umeda, H., Yoshida, H., Umetsu, K., Chiba, H., et al. (1998) · IUBMB Life · doi:10.1080/15216549800203512 · Cited by 207
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., & Kamataki, T. (1998) · Annals of Oncology · doi:10.1023/a:1008438109725 · Cited by 207
Ciotti, M., Marrone, A., Potter, C., & Owens, I. S. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00007 · Cited by 189
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
Guillemette, C., Ritter, J. K., Auyeung, D. J., Kessler, F. K., & Housman, D. E. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00006 · Cited by 169
Self-citationIrinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard
Saltz, L. B., Douillard, J., Pirotta, N., Alakl, M., Gruia, G., Awad, L., Elfring, G. L., Locker, P. K., & Miller, L. L. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-81 · Cited by 146
Irinotecan (CPT-11): Recent Developments and Future Directions–Colorectal Cancer and Beyond
Rothenberg, M. L. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-66 · Cited by 146
Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., & Hoshi, A. (1993) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1993.tb02031.x · Cited by 142
Ciotti, M., Basu, N. K., Brangi, M., & Owens, I. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0453 · Cited by 141
Lévesque, É., Turgeon, D. K., Carrier, J.-S., Montminy, V., Beaulieu, M., & Bélanger, A. (2001) · Biochemistry · doi:10.1021/bi002607y · Cited by 137
Self-citationVogel, A., Kneip, S., Barut, A., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.28655 · Cited by 135
Albert, C., Vallée, M., Beaudry, G., Bélanger, A., & Hum, D. W. (1999) · Endocrinology · doi:10.1210/endo.140.7.6853 · Cited by 100
Akaba, K., Kimura, T., Sasaki, A., Tanabe, S., Wakabayashi, T., Hiroi, M., Yasumura, S., Maki, K., Aikawa, S., & Hayasaka, K. (1999) · Journal of Human Genetics · doi:10.1007/s100380050100 · Cited by 96
Guillemette, C., Lévesque, É., Beaulieu, M., Turgeon, D. K., Hum, D. W., & Bélanger, A. (1997) · Endocrinology · doi:10.1210/endo.138.7.5226 · Cited by 94
Self-citationTurgeon, D. K., Carrier, J.-S., Lévesque, É., Beatty, B., Bélanger, A., & Hum, D. W. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3374 · Cited by 86
Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma
Munshi, N. C. (2001) · The Oncologist · doi:10.1634/theoncologist.6-suppl_2-17 · Cited by 66
Irinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’tPredictToxicity”?
Ratain, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.7 · Cited by 60
Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Rothenberg, M. L. (1998) · PubMed · Cited by 57
Genomic organization of the UGT2b gene cluster on human chromosome 4q13
Riedy, M., Wang, J.-Y., Miller, A. P., Buckler, A., Hall, J., & Guida, M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00006 · Cited by 49
Ramı́rez, J., Iyer, L., Journault, K., Bélanger, P., Innocenti, F., Ratain, M. J., & Guillemette, C. (2002) · Pharmaceutical Research · doi:10.1023/a:1015341726183 · Cited by 46
Self-citationKudoh, S., Fukuoka, M., Masuda, N., Yoshikawa, A., Kusunoki, Y., Matsui, K., Negoro, S., Takifuji, N., Nakagawa, K., Hirashima, T., et al. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03071.x · Cited by 38
Optimizing the Use of Irinotecan in Colorectal Cancer
Cunningham, D., Maroun, J. A., Vanhoefer, U. J., & Cutsem, E. V. (2001) · The Oncologist · doi:10.1634/theoncologist.6-suppl_4-17 · Cited by 37
Guillemette, C. (1997) · Endocrinology · doi:10.1210/en.138.7.2998 · Cited by 31
Self-citation
Cited by
Pharmacogenomics of human UDP-glucuronosyltransferase enzymes
Guillemette, C. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500171 · Cited by 425
Self-citationde Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Zorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376
Okajima, D., Yasuda, S., Maejima, T., Karibe, T., Sakurai, K., Aida, T., Toki, T., Yamaguchi, J., Kitamura, M., Kamei, R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0206 · Cited by 339
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
Metadata
- Authors
- Gagné, J.-F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., & Guillemette, C.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 62
- Issue
- 3
- Pages
- 608-617
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2061132293
- Cited by
- 346
- References
- 36
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.